MARKET

XNCR

XNCR

Xencor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.23
-0.22
-0.98%
After Hours: 22.23 0 0.00% 16:01 05/25 EDT
OPEN
22.42
PREV CLOSE
22.45
HIGH
23.07
LOW
22.05
VOLUME
222.52K
TURNOVER
0
52 WEEK HIGH
43.61
52 WEEK LOW
21.98
MARKET CAP
1.32B
P/E (TTM)
12.61
1D
5D
1M
3M
1Y
5Y
CRISPR, Xencor stock falls as Piper Sandler slashes price target in biotech space
Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech
Seekingalpha · 2d ago
Piper Sandler Adjusts Xencor Price Target to $42 From $66, Maintains Overweight Rating
MT Newswires · 2d ago
--Berenberg Bank Adjusts Xencor's Price Target to $48 From $55, Maintains Buy Rating
MT Newswires · 05/09 07:53
Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues
Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.
Zacks · 05/06 14:24
Zacks.com featured highlights Xencor, Encore Wire and Silvergate Capital
Xencor, Encore Wire and Silvergate Capital have been highlighted in this Screen of The Week article.
Zacks · 05/06 09:38
Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:25
Xencor GAAP EPS of $0.39 beats by $1.03, revenue of $85.5M beats by $59.33M
Xencor press release (NASDAQ:XNCR): Q1 GAAP EPS of $0.39 beats by $1.03. Revenue of $85.5M (+152.2% Y/Y) beats by $59.33M. Cash, cash equivalents, receivables and marketable debt securities totaled $683.6
Seekingalpha · 05/05 21:05
Xencor Q1 EPS $0.39 Up From $(0.04) YoY, Sales $85.50M Up From $33.97M YoY
Xencor (NASDAQ:XNCR) reported quarterly earnings of $0.39 per share. This is a 1075 percent increase over losses of $(0.04) per share from the same period last year. The company reported $85.50 million in sales this
Benzinga · 05/05 20:39
More
No Data
Learn about the latest financial forecast of XNCR. Analyze the recent business situations of Xencor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
64.29%Buy
0.00%Hold
7.14%Under-perform
0.00%Sell
Analyst Price Target
The average XNCR stock price target is 50.00 with a high estimate of 60.00 and a low estimate of 30.00.
High60.00
Average50.00
Low30.00
Current 22.23
EPS
Actual
Estimate
-0.250.190.631.07
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 243
Institutional Holdings: 63.81M
% Owned: 107.17%
Shares Outstanding: 59.54M
TypeInstitutionsShares
Increased
61
1.56M
New
31
1.89M
Decreased
58
1.86M
Sold Out
19
562.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
President/Chief Executive Officer/Founder/Director
Bassil Dahiyat
Chief Financial Officer/Senior Vice President
John Kuch
Senior Vice President/Chief Scientific Officer
John Desjarlais
Senior Vice President/General Counsel/Secretary
Celia Eckert
Senior Vice President
Allen Yang
Lead Director/Independent Director
A. Bruce Montgomery
Independent Director
Ellen Feigal
Independent Director
Kevin Gorman
Independent Director
Kurt Gustafson
Independent Director
Yujiro Hata
Independent Director
Richard Ranieri
Independent Director
Dagmar Rosa-Bjorkeson
No Data
No Data
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.

Webull offers kinds of Xencor Inc stock information, including NASDAQ:XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.